NCT05308589 (FLUID) is a NA clinical trial of CPPF in Cardiac Surgical Procedures, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Who is sponsoring NCT05308589?

NCT05308589 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

What drugs are being tested in NCT05308589?

Interventions in NCT05308589: CPPF.

What condition does NCT05308589 study?

NCT05308589 studies Cardiac Surgical Procedures, Retained Blood Syndrome, Cardiac Tamponade, Postoperative Hemorrhage.

Is NCT05308589 still recruiting?

NCT05308589 is currently terminated. Last updated 14 May 2024.

Last reviewed 2024-05-14 · How we verify

NCT05308589: FLUID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CPPF After General Cardiac Surgery

Terminated NA Last updated 14 May 2024

What this trial tests

NA trial testing CPPF in Cardiac Surgical Procedures in 164 participants. Terminated before completion.

Timeline

2 November 2021

Primary endpoint
18 April 2023

18 April 2023

Quick facts

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	164
Start date	2 November 2021
Primary completion	18 April 2023
Estimated completion	18 April 2023
Sites	4 locations across Netherlands

Drugs / interventions tested

CPPF

Conditions studied

Cardiac Surgical Procedures — all drugs for Cardiac Surgical Procedures →
Retained Blood Syndrome — all drugs for Retained Blood Syndrome →
Cardiac Tamponade — all drugs for Cardiac Tamponade →
Postoperative Hemorrhage — all drugs for Postoperative Hemorrhage →

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

18 and older, any sex, with Cardiac Surgical Procedures or Retained Blood Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In two randomized clinical trials the investigators have demonstrated that continuous postoperative pericardial flushing (CPPF) therapy can reduce postoperative blood loss and bleeding-related complications after cardiac surgery and that CPPF therapy is safe and feasible in an experimental setting. The Haermonics investigational device is a novel medical device that enables CPPF therapy to be used in daily clinical setting. The aim of this study is three-fold. First, to evaluate the safety and functionality of the Haermonics investigational device. Secondly, to investigate the effect of CPPF therapy on bleeding related complications in the adulty cardiac surgery population. Thirdly, to explore the effect of CPPF therapy on intraluminal chest tube clogging.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Continuous Postoperative Pericardial FLUshing with Investigational Device on Postoperative Re-Explorations for Bleeding (FLUID)-Randomized Clinical Trial.
Molenaar MA, Koolbergen DR, Vegter M, Lam K, et al · · 2026 · PMID 41899076 · DOI 10.3390/jcm15062151

Verify or expand the search:

Other recruiting trials for Cardiac Surgical Procedures

Currently open trials in the same condition.

NCT07348510 — Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures · NA · recruiting
NCT06952907 — Femoral Versus Radial Invasive Arterial Pressure Monitoring in Cardiac Surgery Patients · NA · recruiting
NCT06318689 — In Situ Exploration of Vascular Function in Vasoplegic Shock Following Cardiac Surgery With Cardiopulmonary Bypass · recruiting
NCT04244981 — Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery · Phase 4 · recruiting

Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials

Trials by the same sponsor.

NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05308589 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Last refreshed: 14 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05308589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing